Recombinant Human Galectin 1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02107P-100UG
Human Galectin 1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human Galectin 1 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02107P-100UG
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human Galectin 1 Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Ala2-Asp135. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | P09382 |
Target Symbol | GAL1 |
Synonyms | Galectin-1; HLBP14; S-Lac lectin 1; LGALS1; GAL1; GBP; DKFZp686E23103 |
Species | Human |
Expression System | HEK293 |
Tag | N-hFc |
Expression Range | Ala2-Asp135 |
Mol. Weight | The protein has a predicted MW of 41.9 kDa. Due to glycosylation, the protein migrates to 48-55 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human Galectin 1, hFc Tag at 1ug/ml (100ul/Well) on the plate. Dose response curve for Biotinylated Anti-Galectin 1 Antibody, hFc Tag with the EC50 of 41.1ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Galectin 1(Gal-1), a β-galactoside binding mammalian lectin of 14KDa, is implicated in many signalling pathways, immune responses associated with cancer progression and immune disorders. Inhibition of human Gal-1 has been regarded as one of the potential therapeutic approaches for the treatment of cancer, as it plays a major role in tumour development and metastasis by modulating various biological functions viz. apoptosis, angiogenesis, migration, cell immune escape. |